patients with her2+ brain mets live twice as long as those with her2-

[Lani]

ABSTRACT: HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients [The Breast]
The aim of this retrospective study was to examine the influence of HER2 status on outcome in breast cancer patients following whole brain radiotherapy (WBRT) for cerebral metastases. One hundred and eighty one patients with recordable HER2 status, who received WBRT at single institution were identified and stratified according to HER2 status. Eighty eight were HER2 positive (HER2+) (49%) and 93 HER2 negative (HER2-) (51%). A total of 72 (82%) HER2+ group developed brain metastases whilst on chemotherapy compared with 45 (48%) in HER2- group. Median survival after WBRT was 8 months (1-38) for HER2+ patients and 4 (1-64) for HER2- patients p = 0.01. On brain metastasis progression, 18 (20%) of HER2+ patients received further local therapy compared with 6 (6%) in HER2- group. This study shows superior survival in HER2+ group following WBRT as compared to HER2- group

Many on these boards have FAR EXCEEDED these stats. Too bad a study of those here could never be considered randomized...there is a selection bias for intelligent, web-savvy and enabled, motivated ladies